Abstract: There is provided a vector for treating retinal degeneration associated with Bardet-Biedl Syndrome (BBS), wherein the vector comprises a promoter operably linked to a BBS1 gene, wherein the promoter is selected from a rhodopsin kinase (RK) promoter, a cytomegalovirus immediate-early (CMV) promoter and a CAG promoter, and wherein the vector is selected from an AAV2/8 vector, an AAV2/7m8 vector and an AAV9 vector. Also disclosed is a pharmaceutical composition comprising the vector, and use of the vector in a method of treating retinal degeneration associated with BBS comprising administering a therapeutically effective amount of the vector to a patient suffering from BBS, wherein the vector is administered directly to the eye of the patient.

Abstract: A system and process unifies DNS/Naming registration, trusted SSL certificate generation and signing. While installing a product, a customer registers it. This automatically enables the customer to use the DNS/Naming registration service offered by the entity, which automatically assigns a customer specified symbolic name for the product so that it can easily be found on the Internet. This is done simply and inexpensively by piggybacking on one of the domains owned by the entity. Once this happens, a SSL certificate is created and signed based on the subdomain. No verification of the SSL certificate is required, since the subdomain was assigned by the entity and it knows to whom it was assigned.